Companies › ScandiBio Therapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Neurology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CMA2 Combined metabolic activator containing N-acetyl-L-cysteine, L-carnitine-L-tartrate, nicot | NAC, LCAT, NICOTINAMIDE, L-SERINE | Phase 3 | Alzheimer Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07062198 | CMA2 | Phase 3 | Alzheimer Disease | Neurology | Sep 2026 |
–
Prilenia Ambros Therapeutics Cerevance Green Valley (Shanghai) Pharmaceuticals CereMark Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.